Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectivePopulation pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosisPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levelsTargeted versus universal antifungal prophylaxis among liver transplant recipientsAchieving target voriconazole concentrations more accurately in children and adolescents.Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.In vitro study of the variable effects of proton pump inhibitors on voriconazoleMulticenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignanciesRelationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.Anti-Aspergillus Prophylaxis in Lung Transplantation: A Systematic Review and Meta-analysis.Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.Adrenal Insufficiency With Voriconazole and Inhaled/Intranasal Corticosteroids: Case Report and Systematic Review.Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Fungal Infections After Lung Transplantation.Uptake and efflux kinetics, and intracellular activity of voriconazole against Aspergillus fumigatus in human pulmonary epithelial cells: a new application for the prophylaxis and early treatment of invasive pulmonary aspergillosis.Dosing and therapeutic drug monitoring of voriconazole in bottlenose dolphins (Tursiops truncatus).Utility of voriconazole therapeutic drug monitoring: a meta-analysis.10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation.Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.Epidemiology of invasive fungal infections in lung transplant recipients on long-term azole antifungal prophylaxis.Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient VariabilityVoriconazole and the liver.Emerging fungal infections in solid organ transplantation.Candida infections in solid organ transplantation.Epidemiology and outcomes of deep surgical site infections following lung transplantation.Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.Aspergillosis prophylaxis with voriconazole for 90 days in high-risk liver transplant recipients: Right drug and duration?A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.
P2860
Q27009221-211963FD-3792-4FFB-BBBB-6CE89C2A4FD1Q34020402-95845BCF-8733-44E8-9191-53FBDA0803D9Q34532546-7570E373-6899-4B1D-9798-7CE2D09F3B35Q35105949-B0CA48A0-087E-4FD0-8C29-643F2D9AECEBQ35169112-AEA14A60-6178-461C-83A9-661461ED9FBAQ35194743-BA4C9B7F-70A0-437E-9992-D1B2E91D00FAQ35607652-B91EE568-4620-4B9D-84DC-1976AC574A37Q35954530-8DB5144B-14D5-4AF8-935E-09B3A7FD38C5Q35960842-444B55AE-A82A-46DE-A115-08E6B75EE47BQ36172497-C4B54D16-4C3F-4E5A-843D-4287BFA410E1Q36276966-128BE64D-A5A4-4EF0-94FF-B92C6A33EC19Q36608562-0865401C-0A17-4CEA-83F6-4755EBD9BF90Q36658777-5C328D9A-1AAB-41DC-B3D2-DC152C7EC165Q36849416-2B974510-395D-4B6C-8B56-E5203950CC77Q36969780-8A4737A9-D833-4311-BD70-9E1F89712131Q37124182-DFA2CC02-49D1-4CE3-A673-8574E5E5EBE0Q37688257-CE89AF6B-63A9-4A9F-9D56-AC117C5D107CQ38140015-37182C89-70F2-4938-B4C0-F17010810530Q38156666-57F401C9-FEF5-471C-960F-FF6BDD6075B4Q38362057-74D286D6-34B5-414C-8965-9135BAADDFEDQ38526795-9EC2A83D-D74A-41B3-8E84-9060453A39B9Q38826212-4526AB82-3112-46CB-BF71-95AC079C43A2Q38880522-34FA65B7-B592-4653-BC4F-5FCE912A6846Q40098248-EAE3DF6F-61B6-4B9B-B38A-7F7067E001C2Q40396776-9CCBB77D-10A9-4B31-BE90-322A47F147E1Q40487869-6E64AD7C-F6D4-4608-9642-C598FCA5A678Q40679884-43927736-07FF-44B0-B52B-44C9E923B3C2Q41015559-BA6D1C89-B1E2-4F8D-A582-F23A1E758BEAQ41284722-B22EE5CF-24A0-4C03-8B68-F7904F24EC21Q41532401-90B697CD-AF72-45AF-8D3F-D1DB64C35CC6Q41991703-40D5B24C-7589-4EBF-9792-0237062AC068Q42027433-A01F27B7-0CC2-4873-9143-8FCB8F4E1CD7Q42272283-ACC05A79-90E0-4C38-8068-3789CBA63B80Q42272295-D0F7FF51-BA9C-40DB-AA5D-138FDDC7B045Q44448738-5B0B0062-C657-42CA-8E89-28259AC67637Q46119145-21D2C5F7-2FF8-405C-8EE4-DE7A1451151AQ47664190-F1EBEF6C-3CDE-4437-8EC9-D6A6B9485B30Q54728601-3E8F46E0-4213-47F2-8634-F79E257904EEQ55479804-6162F3A7-24DC-4429-B313-3DA786ACFB4D
P2860
Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Prospective, observational stu ...... roughs, efficacy, and toxicity
@ast
Prospective, observational stu ...... roughs, efficacy, and toxicity
@en
type
label
Prospective, observational stu ...... roughs, efficacy, and toxicity
@ast
Prospective, observational stu ...... roughs, efficacy, and toxicity
@en
prefLabel
Prospective, observational stu ...... roughs, efficacy, and toxicity
@ast
Prospective, observational stu ...... roughs, efficacy, and toxicity
@en
P2093
P2860
P356
P1476
Prospective, observational stu ...... roughs, efficacy, and toxicity
@en
P2093
Christian Bermudez
Cornelius J Clancy
Dimitra Mitsani
Eun J Kwak
Fernanda P Silveira
Jay K Bhama
Joseph M Pilewski
M Hong Nguyen
Maria M Crespo
Ryan K Shields
P2860
P304
P356
10.1128/AAC.05219-11
P407
P577
2012-02-13T00:00:00Z